AR109948A1 - Anticuerpos anti-il-33 y usos de los mismos - Google Patents
Anticuerpos anti-il-33 y usos de los mismosInfo
- Publication number
- AR109948A1 AR109948A1 ARP170102863A ARP170102863A AR109948A1 AR 109948 A1 AR109948 A1 AR 109948A1 AR P170102863 A ARP170102863 A AR P170102863A AR P170102863 A ARP170102863 A AR P170102863A AR 109948 A1 AR109948 A1 AR 109948A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibodies
- human
- same
- lcdr2s
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente solicitud proporciona anticuerpos los cuales se unen y neutralizan IL-33 humano, y métodos para usar los mismos, tales anticuerpos son útiles como agentes para el tratamiento de condiciones asociadas con enfermedad alérgica que incluye tratar dermatitis atópica. Reivindicación 1: Un anticuerpo que se une a IL-33 humano, caracterizado porque comprende dos LCDR1s, cada una de la SEQ ID Nº 16, dos LCDR2s, cada una de la SEQ ID Nº 17, dos LCDR3s, cada una de la SEQ ID Nº 18, dos HCDR1s, cada una de la SEQ ID Nº 13, dos HCDR2s, cada una de la SEQ ID Nº 14, y dos HCDR3s, cada una de la SEQ ID Nº 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414258P | 2016-10-28 | 2016-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109948A1 true AR109948A1 (es) | 2019-02-06 |
Family
ID=60263117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102863A AR109948A1 (es) | 2016-10-28 | 2017-10-13 | Anticuerpos anti-il-33 y usos de los mismos |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10501536B2 (es) |
| EP (1) | EP3532499B1 (es) |
| JP (1) | JP6830533B2 (es) |
| KR (1) | KR102266144B1 (es) |
| CN (1) | CN109863173B (es) |
| AR (1) | AR109948A1 (es) |
| AU (1) | AU2017351183B2 (es) |
| BR (1) | BR112019005139A2 (es) |
| CA (1) | CA3039232C (es) |
| CL (1) | CL2019001043A1 (es) |
| CO (1) | CO2019003047A2 (es) |
| CR (1) | CR20190179A (es) |
| CY (1) | CY1124360T1 (es) |
| DK (1) | DK3532499T3 (es) |
| EA (1) | EA201990778A1 (es) |
| EC (1) | ECSP19029758A (es) |
| ES (1) | ES2878037T3 (es) |
| HR (1) | HRP20211221T1 (es) |
| HU (1) | HUE055621T2 (es) |
| IL (1) | IL265689B2 (es) |
| JO (1) | JOP20190093A1 (es) |
| LT (1) | LT3532499T (es) |
| MA (1) | MA46619B1 (es) |
| MD (1) | MD3532499T2 (es) |
| MX (1) | MX394799B (es) |
| PE (1) | PE20191045A1 (es) |
| PH (1) | PH12019500929A1 (es) |
| PL (1) | PL3532499T3 (es) |
| PT (1) | PT3532499T (es) |
| RS (1) | RS62120B1 (es) |
| SI (1) | SI3532499T1 (es) |
| SM (1) | SMT202100442T1 (es) |
| TN (1) | TN2019000086A1 (es) |
| TW (2) | TWI676680B (es) |
| UA (1) | UA121293C2 (es) |
| WO (1) | WO2018081075A1 (es) |
| ZA (1) | ZA201901935B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| AU2020368369A1 (en) | 2019-10-15 | 2022-05-12 | Eli Lilly And Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| KR20220093334A (ko) | 2019-11-04 | 2022-07-05 | 메디뮨 리미티드 | Il-33 길항제의 이용 방법 |
| CA3158366A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| WO2021180858A1 (en) | 2020-03-13 | 2021-09-16 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| AU2021253117B2 (en) | 2020-04-06 | 2025-08-14 | Medimmune Limited | Treating acute respiratory distress syndrome with IL-33 axis binding antagonists |
| EP4149521A1 (en) | 2020-05-11 | 2023-03-22 | MedImmune Limited | Formulations of anti-il-33 antibodies |
| CN111620948B (zh) * | 2020-06-10 | 2022-04-08 | 南京赛新生物科技有限公司 | 针对il-33的抗体 |
| CN113603775B (zh) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| WO2024038185A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
| WO2025114862A1 (en) * | 2023-11-27 | 2025-06-05 | Glaxosmithkline Intellectual Property Development Limited | Il-33 binding antibodies |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| EP2152740A1 (en) | 2007-04-26 | 2010-02-17 | Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Products for altering il-33 activity and methods therefor |
| US20100260770A1 (en) | 2007-05-18 | 2010-10-14 | Medimmune, Llc | Il-33 in inflammatory disease |
| WO2011031600A1 (en) * | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| KR102003075B1 (ko) * | 2011-02-23 | 2019-07-23 | 에프. 호프만-라 로슈 아게 | 인간 il33r에 대한 항체 및 이의 용도 |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| US9758578B2 (en) * | 2013-12-26 | 2017-09-12 | Mitsubishi Tanabe Pharma Corporation | Human anti-IL-33 neutralizing monoclonal antibody |
| AU2015204674B2 (en) * | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| WO2015164354A1 (en) * | 2014-04-21 | 2015-10-29 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CA2982400C (en) | 2015-03-31 | 2023-10-24 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| AU2017208099A1 (en) | 2016-01-14 | 2018-08-09 | Anaptysbio, Inc. | Inhibition of allergic reaction using an IL-33 inhibitor |
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0093A patent/JOP20190093A1/ar unknown
- 2017-10-13 TW TW107143762A patent/TWI676680B/zh active
- 2017-10-13 AR ARP170102863A patent/AR109948A1/es unknown
- 2017-10-13 TW TW106135006A patent/TWI647238B/zh active
- 2017-10-24 WO PCT/US2017/058020 patent/WO2018081075A1/en not_active Ceased
- 2017-10-24 EP EP17794593.8A patent/EP3532499B1/en active Active
- 2017-10-24 PL PL17794593T patent/PL3532499T3/pl unknown
- 2017-10-24 BR BR112019005139A patent/BR112019005139A2/pt unknown
- 2017-10-24 PT PT177945938T patent/PT3532499T/pt unknown
- 2017-10-24 DK DK17794593.8T patent/DK3532499T3/da active
- 2017-10-24 RS RS20210875A patent/RS62120B1/sr unknown
- 2017-10-24 CR CR20190179A patent/CR20190179A/es unknown
- 2017-10-24 SM SM20210442T patent/SMT202100442T1/it unknown
- 2017-10-24 MD MDE20190980T patent/MD3532499T2/ro unknown
- 2017-10-24 CN CN201780065572.XA patent/CN109863173B/zh active Active
- 2017-10-24 TN TNP/2019/000086A patent/TN2019000086A1/en unknown
- 2017-10-24 HR HRP20211221TT patent/HRP20211221T1/hr unknown
- 2017-10-24 US US15/791,641 patent/US10501536B2/en active Active
- 2017-10-24 PE PE2019000838A patent/PE20191045A1/es unknown
- 2017-10-24 UA UAA201903400A patent/UA121293C2/uk unknown
- 2017-10-24 ES ES17794593T patent/ES2878037T3/es active Active
- 2017-10-24 MA MA46619A patent/MA46619B1/fr unknown
- 2017-10-24 KR KR1020197012190A patent/KR102266144B1/ko active Active
- 2017-10-24 HU HUE17794593A patent/HUE055621T2/hu unknown
- 2017-10-24 AU AU2017351183A patent/AU2017351183B2/en active Active
- 2017-10-24 EA EA201990778A patent/EA201990778A1/ru unknown
- 2017-10-24 MX MX2019004863A patent/MX394799B/es unknown
- 2017-10-24 CA CA3039232A patent/CA3039232C/en active Active
- 2017-10-24 LT LTEP17794593.8T patent/LT3532499T/lt unknown
- 2017-10-24 IL IL265689A patent/IL265689B2/en unknown
- 2017-10-24 JP JP2019522272A patent/JP6830533B2/ja active Active
- 2017-10-24 SI SI201730830T patent/SI3532499T1/sl unknown
-
2019
- 2019-03-28 CO CONC2019/0003047A patent/CO2019003047A2/es unknown
- 2019-03-28 ZA ZA201901935A patent/ZA201901935B/en unknown
- 2019-04-16 CL CL2019001043A patent/CL2019001043A1/es unknown
- 2019-04-25 PH PH12019500929A patent/PH12019500929A1/en unknown
- 2019-04-26 EC ECSENADI201929758A patent/ECSP19029758A/es unknown
- 2019-10-25 US US16/663,561 patent/US10913793B2/en active Active
-
2021
- 2021-07-26 CY CY20211100672T patent/CY1124360T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109948A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| CY1126255T1 (el) | Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
| EA202090104A1 (ru) | Молекулы антител к cd73 и пути их применения | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| CO2017012553A2 (es) | Moléculas de unión a lag-3 | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| MX388015B (es) | Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer. | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| EA201790530A1 (ru) | Агенты, связывающиеся с cd123, и виды их применения | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| MX393740B (es) | Anticuerpos contra alfa-sinucleina y sus usos. | |
| UY35483A (es) | Anticuerpos pac1 humanos | |
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| ECSP18070641A (es) | Anticuerpos para il-17c | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| EA201991203A1 (ru) | Способы лечения ожирения антителами к angptl8 | |
| MX2022015197A (es) | Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos. | |
| EA201992460A1 (ru) | Антитела-агонисты btla и их применение | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. | |
| UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |